Adjuvant Hormonal Therapy of Breast Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

Thierry Petit ¹ , 任国胜 ² , Patrick Dufour ¹ , 甘露 ²

Corresponding author：

Keywords：

乳腺癌; 辅助内分泌治疗

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： Thierry Petit,任国胜,Patrick Dufour,甘露. Adjuvant Hormonal Therapy of Breast Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2007, 14(3): 248-251. doi: Copy

1.	Osborne CK. Adjuvant endocrine therapy [A]. In: Harris, Lippman, Morrow, et al. Eds. Diseases of the breast [M]. 3rd Ed. USA. Lippincott: Williams & Wilkins, 2004∶865-891.
2.	Early Breast Cancer Trialist’s Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15year survival: an overview of the randomised trials [J]. Lancet， 2005; 365(9472)∶1687.
3.	Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B14 randomized trial [J]. J Natl Cancer Inst, 2001; 93(9)∶684.
4.	Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials [J]. Lancet, 1998; 351(9114)∶1451.
5.	Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review [J]. Cancer Treat Rev, 2002; 28(4)∶165.
6.	Pritchard K. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women [J]. Breast Cancer Res, 2005; 7(2)∶70.
7.	Sharma R, Beith J, Hamilton A. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer [J]. Breast, 2005; 14(3)∶181.
8.	Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? [J]. Oncologist, 2004; 9(5)∶507.
9.	Robert NJ, Wang M, Wood W, et al. Phase Ⅲ comparison of tamoxifen with ovarian ablation in premenopausal women with axillary nodenegative receptor positive breast cancer <3 cm [C]. ASCO, 2003∶16.
10.	Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicinbased chemotherapy in premenopausal, one to three nodepositive, and hormonereceptor positive, early breast cancer patients: 7year followup results of French Adjuvant Study Group 06 randomised trial [J]. Ann Oncol， 2006; 17(8)∶1221.
11.	Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormoneresponsive breast cancer——ustrian Breast and Colorectal Cancer Study Group Trial 5 [J]. J Clin Oncol， 2002; 20(24)∶4621.
12.	Del Mastro L, Venturini M, Sertoli MR, et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications [J]. Breast Cancer Res Treat, 1997; 43(2)∶183.
13.	Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph nodepositive, steroid hormone receptorpositive breast cancer: results from INT 0101 (E5188) [J]. J Clin Oncol, 2005; 23(25)∶5973.
14.	de Cremoux P, Dieras V, Poupon MF, et al. Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects [J]. Bull Cancer, 2004; 91(12)∶917.
15.	Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer [J]. Lancet, 2005; 365(9453)∶60.
16.	Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [J]. N Engl J Med, 2005; 353(26)∶2747.
17.	Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. N Engl J Med, 2004; 350(11)∶1081.
18.	Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial [J]. Lancet, 2005; 366(9484)∶455.
19.	Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial [J]. J Clin Oncol, 2005; 23(22)∶5138.
20.	Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: updated findings from NCIC CTG MA.17 [J]. J Natl Cancer Inst, 2005; 97(17)∶1262.
21.	Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole : Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a [C]. ASCO, 2005∶527.
22.	Mamounas E， Jeong JH, Wickerham L, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intenttotreat analysis of NSABP B33 [C]. SABCS, 2006∶49.
23.	Goss PE, Ingle JN, Palmer MJ, et al. Updated analysis of NCIC CTG MA 17 post unblinding [C]. SABCS, 2005∶16.
24.	Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive earlystage breast cancer: a metaanalysis [J]. Lancet Oncol, 2006; 7(12)∶991.
25.	Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy [J]. J Clin Oncol, 1996; 14(10)∶2738.
26.	Cancers du sein : Recommandations pour la pratique clinique de SaintPauldeVence [J]. Oncologie, 2005; 7(5)∶342.
27.	Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 [J]. Ann Oncol, 2005; 16(10)∶1569.
28.	Winer EP. Optimizing endocrine therapy for breast cancer [J]. J Clin Oncol, 2005; 23(8)∶1609.

1. Osborne CK. Adjuvant endocrine therapy [A]. In: Harris, Lippman, Morrow, et al. Eds. Diseases of the breast [M]. 3rd Ed. USA. Lippincott: Williams & Wilkins, 2004∶865-891.
2. Early Breast Cancer Trialist’s Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15year survival: an overview of the randomised trials [J]. Lancet， 2005; 365(9472)∶1687.
3. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen for lymph nodenegative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B14 randomized trial [J]. J Natl Cancer Inst, 2001; 93(9)∶684.
4. Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials [J]. Lancet, 1998; 351(9114)∶1451.
5. Clemons M, Danson S, Howell A. Tamoxifen (“Nolvadex”): a review [J]. Cancer Treat Rev, 2002; 28(4)∶165.
6. Pritchard K. Endocrinology and hormone therapy in breast cancer: endocrine therapy in premenopausal women [J]. Breast Cancer Res, 2005; 7(2)∶70.
7. Sharma R, Beith J, Hamilton A. Systematic review of LHRH agonists for the adjuvant treatment of early breast cancer [J]. Breast, 2005; 14(3)∶181.
8. Prowell TM, Davidson NE. What is the role of ovarian ablation in the management of primary and metastatic breast cancer today? [J]. Oncologist, 2004; 9(5)∶507.
9. Robert NJ, Wang M, Wood W, et al. Phase Ⅲ comparison of tamoxifen with ovarian ablation in premenopausal women with axillary nodenegative receptor positive breast cancer <3 cm [C]. ASCO, 2003∶16.
10. Roche H, Kerbrat P, Bonneterre J, et al. Complete hormonal blockade versus epirubicinbased chemotherapy in premenopausal, one to three nodepositive, and hormonereceptor positive, early breast cancer patients: 7year followup results of French Adjuvant Study Group 06 randomised trial [J]. Ann Oncol， 2006; 17(8)∶1221.
11. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormoneresponsive breast cancer——ustrian Breast and Colorectal Cancer Study Group Trial 5 [J]. J Clin Oncol， 2002; 20(24)∶4621.
12. Del Mastro L, Venturini M, Sertoli MR, et al. Amenorrhea induced by adjuvant chemotherapy in early breast cancer patients: prognostic role and clinical implications [J]. Breast Cancer Res Treat, 1997; 43(2)∶183.
13. Davidson NE, O’Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph nodepositive, steroid hormone receptorpositive breast cancer: results from INT 0101 (E5188) [J]. J Clin Oncol, 2005; 23(25)∶5973.
14. de Cremoux P, Dieras V, Poupon MF, et al. Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects [J]. Bull Cancer, 2004; 91(12)∶917.
15. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer [J]. Lancet, 2005; 365(9453)∶60.
16. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer [J]. N Engl J Med, 2005; 353(26)∶2747.
17. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J]. N Engl J Med, 2004; 350(11)∶1081.
18. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial [J]. Lancet, 2005; 366(9484)∶455.
19. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial [J]. J Clin Oncol, 2005; 23(22)∶5138.
20. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptorpositive breast cancer: updated findings from NCIC CTG MA.17 [J]. J Natl Cancer Inst, 2005; 97(17)∶1262.
21. Jakesz R, Samonigg H, Greil R, et al. Extended adjuvant treatment with anastrozole : Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a [C]. ASCO, 2005∶527.
22. Mamounas E， Jeong JH, Wickerham L, et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intenttotreat analysis of NSABP B33 [C]. SABCS, 2006∶49.
23. Goss PE, Ingle JN, Palmer MJ, et al. Updated analysis of NCIC CTG MA 17 post unblinding [C]. SABCS, 2005∶16.
24. Jonat W, Gnant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormonesensitive earlystage breast cancer: a metaanalysis [J]. Lancet Oncol, 2006; 7(12)∶991.
25. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy [J]. J Clin Oncol, 1996; 14(10)∶2738.
26. Cancers du sein : Recommandations pour la pratique clinique de SaintPauldeVence [J]. Oncologie, 2005; 7(5)∶342.
27. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005 [J]. Ann Oncol, 2005; 16(10)∶1569.
28. Winer EP. Optimizing endocrine therapy for breast cancer [J]. J Clin Oncol, 2005; 23(8)∶1609.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Adjuvant Hormonal Therapy of Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content